Abstract:Background Prognostic genes in the tumor microenvironment play an important role in immune biological processes and the response of cancer to immunotherapy. Thus, we aimed to assess new biomarkers that are associated with immune/stromal cells in lung adenocarcinomas (LUAD) using the ESTIMATE algorithm, which also significantly affects the prognosis of cancer. Methods The RNA sequencing (RNA-Seq) and clinical data of LUAD were downloaded from the the Cancer Genome Atlas (TCGA ). The immune and stromal scores were calculated for each sample using the ESTIMATE algorithm. The LUAD gene chip expression profile data and the clinical data ( GSE37745 , GSE11969 , and GSE50081 ) were downloaded from the Gene Expression Omnibus (GEO) for subsequent validation analysis. Differentially expressed genes were calculated between high and low score groups. Univariate Cox regression analysis was performed on differentially expressed genes (DEGs) between the two groups to obtain initial prognosis genes. These were verified by three independent LUAD cohorts from the GEO database. Multivariate Cox regression was used to identify overall survival-related DEGs. UALCAN and the Human Protein Atlas were used to analyze the mRNA /protein expression levels of the target genes. Immune cell infiltration was evaluated using the Tumor Immune Estimation Resource (TIMER) and CIBERSORT methods, and stromal cell infiltration was assessed using xCell. Results In this study, immune scores and stromal scores are significantly associated with the clinical characteristics of LUAD, including T stage, M stage, pathological stage, and overall survival time. 530 DEGs (18 upregulated and 512 downregulated) were found to coexist in the difference analysis with the immune scores and stromal scores subgroup. Univariate Cox regression analysis showed that 286 of the 530 DEGs were survival-related genes ( p < 0.05). Of the 286 genes initially identified, nine prognosis-related genes (CSF2RB, ITK, FLT3, CD79A, CCR4, CCR6, DOK2, AMPD1, and IGJ) were validated from three separate LUAD cohorts. In addition, functional analysis of DEGs also showed that various immunoregulatory molecular pathways, including regulation of immune response and the chemokine signaling pathways, were involved. Five genes (CCR6, ITK, CCR4, DOK2, and AMPD1) were identified as independent prognostic indicators of LUAD in specific data sets. The relationship between the expression levels of these genes and immune genes was assessed. We found that CCR6 mRNA and protein expression levels of LUAD were greater than in normal tissues. We evaluated the infiltration of immune cells and stromal cells in groups with high and low levels of expression of CCR6 in the TCGA LUAD cohort. In summary, we found a series of prognosis-related genes that were associated with the LUAD tumor microenvironment.

Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC)

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Identification of prognostic genes in lung adenocarcinoma immune microenvironment

Characterizing Tumor Microenvironment and Risk Genes in Lung Adenocarcinoma through scRNA-seq and Bulk RNA-seq Data

Identification of Genes with Therapeutic and Prognostic Values in Lung Adenocarcinoma Microenvironment

Immune Profile of the Tumor Microenvironment and the Identification of a Four-Gene Signature for Lung Adenocarcinoma

Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma

Systemic immune microenvironment and regulatory network analysis in patients with lung adenocarcinoma

Identification of Immune-Related Gene Signature Predicting Survival in the Tumor Microenvironment of Lung Adenocarcinoma.

An Investigation to Identify Tumor Microenvironment-Related Genes of Prognostic Value in Lung Squamous Cell Carcinoma Based on the Cancer Genome Atlas

A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Integration of Multiple Key Molecules in Lung Adenocarcinoma Identifies Prognostic and Immunotherapeutic Relevant Gene Signatures.

Transcriptional Characterization of the Tumor Immune Microenvironment and Its Prognostic Value for Locally Advanced Lung Adenocarcinoma in A Chinese Population

The Tumor Environment Immune Phenotype of LUSC by Genome-Wide Analysis

Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses

Identification of an Immune Classification and Prognostic Genes for Lung Adenocarcinoma Based on Immune Cell Signatures

Prognostic characteristics of T-cell mediated cell killing-related genes in lung adenocarcinoma

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma

Analysis of genetic mutations associated with immune-activated microenvironment in lung adenocarcinoma.

Identification of immune-associated prognostic biomarkers in lung adenocarcinoma on the basis of gene co-expression network